MS analyses were performed by the Proteomics Research Infrastructure (PRI) at the University of Copenhagen (UCPH), supported by the Novo Nordisk Foundation (NNF) (grant number NNF19SA0059305)
This work expands our understanding of GLP-1R activation and provides valuable insights into potential application of ago-allosterism in drug discovery
"I think ideally this medicine will be for people who haven't tried a weight loss drug yet," he says
If these become chronic problems, then, of course, they can be more damaging to the teeth, throat and esophagus, Garcia-Web noted
Given the FDAs prior position statement, however, and recent trend towards tightened oversight of GLP-1 compounding, future guidance is anticipated